Ex-Pharmacyclics team raises $33.5M for checkpoint drug

Richard Miller

Ex-Pharmacyclics CEO Richard Miller is looking for a second act in biotech with his startup Corvus Pharmaceuticals. Dow Jones reports on the Burlingame, CA-based biotech's plans after its $33.5 million venture round, which was led by OrbiMed. Central to its future is a checkpoint inhibitor, which Miller says targets a new and undisclosed protein. Miller created the company with the help of another ex-Pharmacyclics exec, Joseph Buggy, and OrbiMed Private Equity Partner Peter Thompson. A Phase Ib study is expected to get started in early 2016. Story